Advances in KRASG12D-targeted therapy: from small-molecule inhibitors to PROTACs and molecular glues.
KRAS gene mutations represent one of the most common drivers of human cancers, with particularly high prevalence in pancreatic, lung, and colorectal cancers. Among these, the KRASG12D mutation has long been considered an "undruggable" target because of its unique structural characteristics. This article systematically...